Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers : Challenges and potentials for human applications
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved..
Near-InfraRed PhotoImmunoTherapy (NIR-PIT) is a novel cancer-targeted treatment effected by a chemical conjugation between a photosensitiser (e.g. the NIR phthalocyanine dye IRDye700DX) and a cancer-targeting moiety (e.g. a monoclonal antibody, moAb). Delivery of a conjugate in vivo leads to accumulation at the tumour cell surface by binding to cell surface receptors or antigens. Upon deployment of focal NIR-light, irradiation of the conjugate results in a rapid, targeted cell death. However, the mechanisms of action to produce the cytotoxic effects have yet to be fully understood. Herein, we bring together the current knowledge of NIR-PIT from preclinical and clinical studies in a variety of cancers highlighting the key unanswered research questions. Furthermore, we discuss how to enhance the local control of solid cancers using this novel treatment regimen.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:161 |
|---|---|
| Enthalten in: |
Critical reviews in oncology/hematology - 161(2021) vom: 01. Mai, Seite 103325 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Paraboschi, Irene [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.06.2021 Date Revised 15.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.critrevonc.2021.103325 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323913385 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323913385 | ||
| 003 | DE-627 | ||
| 005 | 20231225185210.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2021.103325 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1079.xml |
| 035 | |a (DE-627)NLM323913385 | ||
| 035 | |a (NLM)33836238 | ||
| 035 | |a (PII)S1040-8428(21)00113-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Paraboschi, Irene |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers |b Challenges and potentials for human applications |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.06.2021 | ||
| 500 | |a Date Revised 15.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Near-InfraRed PhotoImmunoTherapy (NIR-PIT) is a novel cancer-targeted treatment effected by a chemical conjugation between a photosensitiser (e.g. the NIR phthalocyanine dye IRDye700DX) and a cancer-targeting moiety (e.g. a monoclonal antibody, moAb). Delivery of a conjugate in vivo leads to accumulation at the tumour cell surface by binding to cell surface receptors or antigens. Upon deployment of focal NIR-light, irradiation of the conjugate results in a rapid, targeted cell death. However, the mechanisms of action to produce the cytotoxic effects have yet to be fully understood. Herein, we bring together the current knowledge of NIR-PIT from preclinical and clinical studies in a variety of cancers highlighting the key unanswered research questions. Furthermore, we discuss how to enhance the local control of solid cancers using this novel treatment regimen | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a In vitro | |
| 650 | 4 | |a In vivo | |
| 650 | 4 | |a Local control | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a Near-InfraRed fluorophores | |
| 650 | 4 | |a PhotoImmunoTherapy | |
| 650 | 4 | |a Solid cancers | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Immunoconjugates |2 NLM | |
| 650 | 7 | |a Photosensitizing Agents |2 NLM | |
| 700 | 1 | |a Turnock, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Kramer-Marek, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Musleh, Layla |e verfasserin |4 aut | |
| 700 | 1 | |a Barisa, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, John |e verfasserin |4 aut | |
| 700 | 1 | |a Giuliani, Stefano |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical reviews in oncology/hematology |d 1996 |g 161(2021) vom: 01. Mai, Seite 103325 |w (DE-627)NLM012606006 |x 1879-0461 |7 nnns |
| 773 | 1 | 8 | |g volume:161 |g year:2021 |g day:01 |g month:05 |g pages:103325 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.critrevonc.2021.103325 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 161 |j 2021 |b 01 |c 05 |h 103325 | ||